Cel-Sci Corp. Tuesday said it has started a second Phase IIstudy of its BC-IL lymphokine cocktail, in malignant melanomathat has metastasized and has failed to respond to othertherapies.
The cell culture-derived mixture of lymphokines currently isin Phase II clinicals for head and neck cancer.
Malignant melanoma is now the fastest-growing cancer in theUnited States, according to the company, which citedestimates that one in 90 people will have the disease by theyear 2000.
(c) 1997 American Health Consultants. All rights reserved.